VCPIP1 and pancreatic adenocarcinoma: Targeting VCPIP1 pharmaceutically via CAS inhibited the progression of PAAD and enhanced sensitivity to GEM treatment, suggesting that blocking VCPIP1 might be a viable strategy for treating Hippo-driven pancreatic adenocarcinoma.